Press & News

ViewReleaseInStandardHtml

Increased distribution of ownership in Boule Diagnostics

In order to create a greater distribution of ownership, and thus to increase the liquidity in Boule Diagnostics shares, six of Boule Diagnostics founders will divest their holding in the company, with no more than 260,000 shares, representing 5.5 percent of the total shares in the company. Redeye has received the contract to manage the transaction. The sales period runs from September 24 through October 4, 2012.

After completion of the above transaction, the sellers will reduce their total holding from 806,506 shares, representing 17.1 percent of the company's shares, to 546,506 shares, representing 11.6 per cent.

For more information, please contact:
Ernst Westman, President and CEO, Boule Diagnostics AB, tel +46 708 60 88 63

The information disclosed in this press release is such that Boule Diagnostics AB is required to make this information public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for publication on September 24, 2012 at 08.00 am (CET).

TO THE EDITORS
About Boule Diagnostics AB
Boule Diagnostics AB is a fast-growing diagnostics company, developing and manufacturing systems and consumables for haematology diagnostics for the public healthcare providers worldwide. The company is primarily focused on small and medium-sized hospitals, clinics and laboratories in outpatient care as well as other diagnostics companies in both human and veterinary haematology. The group is comprised of operating subsidiaries in Sweden, the US and China. Boule Diagnostics' share is, since 2011, traded on NASDAQ OMX Nordic. www.boule.se